close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by PaxMedica, Inc.

PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
From PaxMedica, Inc.
Via GlobeNewswire
Tickers PXMD
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
From PaxMedica, Inc.
Via GlobeNewswire
Tickers PXMD
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
From PaxMedica, Inc.
Via GlobeNewswire
Tickers PXMD
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
From PaxMedica, Inc.
Via GlobeNewswire
Tickers PXMD
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
From PaxMedica, Inc.
Via GlobeNewswire
Tickers PXMD
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
From PaxMedica, Inc.
Via GlobeNewswire
Tickers PXMD
PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)
From PaxMedica, Inc.
Via GlobeNewswire
Tickers PXMD
PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101
From PaxMedica, Inc.
Via GlobeNewswire
Tickers PXMD
PaxMedica Announces 1-for-17 Reverse Stock Split
From PaxMedica, Inc.
Via GlobeNewswire
Tickers PXMD
PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication
From PaxMedica, Inc.
Via GlobeNewswire
Tickers PXMD
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today